FilingReader Intelligence
Lupin follows US glucagon launch with strong Q1 growth
August 11, 2025 at 06:49 AM UTC•By FilingReader AI
Lupin reported sales of INR 6,164 crores in Q1 FY26, up 11.8% year-on-year, with US business sales reaching $282 million, up 22.3%.
EBITDA margins expanded to 26.6% despite increased R&D investment. The company projects full-year EBITDA margins of 24-25%.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:LUPIN•Bombay Stock Exchange
News Alerts
Get instant email alerts when Lupin publishes news
Free account required • Unsubscribe anytime